# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Response	s)														
1. Name and Address of Reporting Person * Mann Brenda			2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]							Direct					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 10/02/2020							VP of Re	search & De	evelopment		
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Form fi	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3)		2. Transaction Date (Month/Day/Year)	any	Code (Instr. 8)		etion			of (D			ollowing	Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	de	V	Amoun	or (D)	Price	e			\ /		
Stock		10/02/2020		F	1)		98	D	\$ 3.88 (2)	17,558			D		
Report on a s	separate line fo	Table II -	Derivative Secur	ties Ac	quire	Pers cont the f	ons what in the constant of th	no resp n this fo splays	orm a a curi enefici	re not requesting the rently valid the realist the rently of the rently of the rentle	uired to res I OMB cont	spond unle	ss	1474 (9-02)	
2	3 Transaction		9 / 1 /	1	s, op						8 Price of	9 Number	of 10	11. Natur	
	Date	Year) Execution Da	te, if Transaction Code			and Expiration Date (Month/Day/Year)		An Un Se (In	mount of nderlying ecurities nstr. 3 and		Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivati Security Direct ( or Indirect)	hip of Indirect Beneficia Ownershi (Instr. 4)		
			Code V	(A)	(D)		*		ion Ti	or					
	AM, MA (  Stock  Report on a s  Conversion or Exercise Price of Derivative	(Street)  AM, MA 02452  (State)  ecurity  2.  Conversion or Exercise Price of Derivative  add Address of Reporting Perenda  (First)  (First)  (Street)  (Street)  AM, MA 02452  (State)  (State)  (State)  (State)	d Address of Reporting Person* enda  (First) (Middle) EGATE PHARMACEUTICALS, I WAVERLY OAKS ROAD, SUITE  (Street)  AM, MA 02452 (State) (Zip)  ecurity 2. Transaction Date (Month/Day/Year)  Table II -  Conversion or Exercise Price of Derivative 3. Transaction Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  3. A. Deemed Execution Date any (Month/Day/Year) (Month/Day/Year)	and Address of Reporting Person and EYEGATE P  EYEGATE P  EYEG]  3. Date of Earlier  10/02/2020  3. Date of Earlier  10/02/2020  4. If Amendment  AM, MA 02452  (Street)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  2. Table II - Derivative Securities beneficially of the conference of Derivative Security  3. Date of Earlier 10/02/2020  4. If Amendment  2. Transaction Date (E.g., puts, calls, we any (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  4. Transaction Code (Instr. 8)	d Address of Reporting Person enda    2. Issuer Name and Ti EYEGATE PHARM [EYEG]  3. Date of Earliest Trans 10/02/2020  4. If Amendment, Date of Earliest Trans 10/02/2020  (Street)    4. If Amendment, Date of Execution Date if (Month/Day/Year)  (Month/Day/Year)    2. Transaction Date (Month/Day/Year)  2. Trable II - Derivative Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  2. Table II - Derivative Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  3. Transaction Date (Month/Day/Year)  2. Table II - Derivative Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  3. Transaction Date (Month/Day/Year)  4. If Amendment, Date (Inst. Securities beneficially owned of (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  4. If Amendment, Date (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  4. If Amendment, Date (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  4. If Amendment, Date (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  4. If Amendment, Date (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  4. If Amendment, Date (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  4. If Amendment, Date (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  4. If Amendment, Date (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  5. Code (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  6. Code (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  7. Code (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))  8. Code (Inst. Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year))	d Address of Reporting Person* enda  2. Issuer Name and Ticker of EYEGATE PHARMAC [EYEG]  3. Date of Earliest Transaction 10/02/2020  4. If Amendment, Date Origin AM, MA 02452  (State)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Table II - Derivative Securities Acquire (æ.g., puts, calls, warrants, op of Derivative Security  2. Transaction Date (Month/Day/Year)  3. Date of Earliest Transaction 10/02/2020  4. If Amendment, Date Origin Execution Date, if any (Month/Day/Year)  2. Table II - Derivative Securities Acquire (æ.g., puts, calls, warrants, op of Derivative Securities Acquire (æ.g., puts, calls, warrants, op of Derivative Securities Acquire (Month/Day/Year)  2. Table II - Derivative Securities Acquire (æ.g., puts, calls, warrants, op of Derivative Securities Acquire (Month/Day/Year)  3. Transaction Date, if any (Month/Day/Year)  4. Transaction Code (Instr. 8)  5. Original PHARMAC EYEGATE PHARMAC E	d Address of Reporting Person enda    Code	d Address of Reporting Person enda    Code   V   Amount	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INCO [EYEG]	and Address of Reporting Person and Content of Person and Content of Person and Content of Person and Content of Person and Person a	Address of Reporting Person— enda  2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]  3. Date of Earliest Transaction (Month/Day/Year) 10/02/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 10/02/2020  5. Report on a separate line for each class of securities beneficially owned directly or indirectly.  Conversion Date (Month/Day/Year) 10/02/2020  1. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Transaction Date (Report on a separate line for each class of securities beneficially owned directly or indirectly.  2. Date Exercisable (Instr. 3)	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC EYEG]  3. Date of Earliest Transaction (Month/Day/Year) 10/02/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 10/02/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 10/02/2020  5. Relationship of Rep. (Che. Property of the Wy of Res. (Che. Property of Res.)  5. Relationship of Rep. (Che. Property of Res.)  6. Individual or Joint/O. From filed by One Rep. Property of Res. (Che. Property of Res.)  6. Individual or Joint/O. From filed by One Rep. Property of Res. (Che. Property of Res.)  8. Report on a separate line for each class of securities beneficially owned directly or indirectly.  9. Code V Amount (D) Price  1. Stock 10/02/2020  1. Stock 10/02/2020  1. Table 1 - Derivative Securities Acquired, Disposed of, or I Portal Interest of Property or Indirectly.  1. Stock 10/02/2020  1. Table 1 - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Car., puts, calls, warrants, options, convertible securities) and Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  1. Stock 1. Derivative Securities Acquired, Disposed of, or Beneficially Owned (Che. Property or Indirectly).  1. Stock 2. Derivative Securities Acquired, Disposed of, or Beneficially Owned (Che. Property or Indirectly).  1. Stock 2. Date Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3) (Instr. 3) (Instr. 3) (Instr. 5) (Instr. 3) (Instr. 5)	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 10/02/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 10/02/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 10/02/2020  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  10/02/2020  1. Stock 10/02/2020  2. Transaction (Month/Day/Year) 10/02/2020  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  1. Stock 10/02/2020  Table II - Derivative Securities Deneficially owned directly or indirectly  Persons who respond to the collection of information contained in this form are not required to respond unlies  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, and 4)  2. Transaction (Month/Day/Year)  1. Stock 10/02/2020  Table II - Derivative Securities Deneficially owned directly or indirectly  Persons who respond to the collection of information contained in this form are not required to respond unlies  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, and 4)  2. Transaction (Month/Day/Year)  Amount (D) Price of (D	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC EYEGATE PHARMACEUTICALS INC Griss)  (Size)  (Zize)  Table 1 - Non-Derivative Securities Acquired, Organization Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Size)  (Zize)  Table 1 - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Size)  Table 1 - Non-Derivative Securities Acquired, Organization Date (Month/Day/Year)  (Month/Day/Year)	

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development			

## **Signatures**

/s/ Sarah Romano, Attorney-in-Fact*	10/05/2020

**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020.
  - The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.88 to \$3.99, inclusive. The reporting
- (2) person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.